[1] Korman AJ, et al. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339. [2] Liu X, et al. Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272-287.e9. [3] Ignatiadis M, et al. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. Ann Oncol. 2014;25(12):2304-2313. [4] Ganesh K, et al. Targeting metastatic cancer. Nat Med. 2021;27(1):34-44. [5] Ward MP, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?. Mol Cancer. 2021;20(1):59. Published 2021 Mar 31. [6] Ward MP, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?. Mol Cancer. 2021;20(1):59. Published 2021 Mar 31. [7] Tang J, et al. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854-855. [8] Sanmamed MF, et al. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175(2):313-326. [9] Twomey JD, et al. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021;23(2):39. Published 2021 Mar 7. [10] Morad G, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309-5337. [10] https://www.fda.gov/search?s=Dostarlimab-gxly&sort_bef_combine=rel_DESC